• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受体外膜肺氧合 (ECMO) 治疗的 COVID-19 患者的临床病程:韩国大邱的一项多中心研究。

Clinical course of COVID-19 patients treated with ECMO: A multicenter study in Daegu, South Korea.

机构信息

Department of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Hospital, Keimyung University College of Medicine, Daegu, Republic of Korea.

Department of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Hospital, Keimyung University College of Medicine, Daegu, Republic of Korea; Department of Thoracic and Cardiovascular Surgery, Keimyung University Daegu Dongsan Hospital, Keimyung University College of Medicine, Daegu, Republic of Korea.

出版信息

Heart Lung. 2021 Jan-Feb;50(1):21-27. doi: 10.1016/j.hrtlng.2020.10.010. Epub 2020 Oct 19.

DOI:10.1016/j.hrtlng.2020.10.010
PMID:34698019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7572066/
Abstract

BACKGROUND

The COVID-19 pandemic has caused an epidemic of critical patients, some of whom have been treated with extracorporeal membrane oxygenation (ECMO). This purpose of study is to describe the clinical course of COVID-19 patients treated with ECMO.

METHODS

A multicentered study of critical patients with COVID-19 treated at six hospitals in Daegu was conducted between January and April 2020.

RESULTS

Among the 80 patients receiving mechanical ventilation support, 19 (24%) were treated with ECMO included (median age 63.0 years). Eight of the 19 patients (42%) were weaned off ECMO (9.8 days, IQR 7.0-13.7). Among them, four patients were also weaned off mechanical ventilation (33.4 days, IQR 29.3 - 35.7), three were still receiving mechanical ventilation (50.9 days), and one expired after ECMO weaning. According to the univariate analysis, the factor that was associated with successful ECMO weaning was vitamin B12 treatment (p = 0.028).

CONCLUSIONS

During the COVID-19 epidemic, ECMO weaning and mortality rates were 42% and 58%, respectively.

摘要

背景

COVID-19 大流行导致危重症患者大量增加,其中一些患者接受了体外膜肺氧合(ECMO)治疗。本研究旨在描述接受 ECMO 治疗的 COVID-19 患者的临床病程。

方法

对 2020 年 1 月至 4 月期间在大邱的六家医院接受机械通气支持的 COVID-19 危重症患者进行了一项多中心研究。

结果

在接受机械通气支持的 80 名患者中,有 19 名(24%)接受 ECMO 治疗(中位年龄 63.0 岁)。在这 19 名患者中,有 8 名(42%)成功撤机(撤机时间为 9.8 天,IQR 7.0-13.7)。其中,4 名患者同时成功撤机机械通气(撤机时间为 33.4 天,IQR 29.3 - 35.7),3 名患者仍在接受机械通气(50.9 天),1 名患者在 ECMO 撤机后死亡。单因素分析显示,维生素 B12 治疗与 ECMO 成功撤机相关(p=0.028)。

结论

在 COVID-19 疫情期间,ECMO 撤机率和死亡率分别为 42%和 58%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d50d/7572066/76b6396333b4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d50d/7572066/7fd1a121f356/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d50d/7572066/76b6396333b4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d50d/7572066/7fd1a121f356/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d50d/7572066/76b6396333b4/gr2_lrg.jpg

相似文献

1
Clinical course of COVID-19 patients treated with ECMO: A multicenter study in Daegu, South Korea.接受体外膜肺氧合 (ECMO) 治疗的 COVID-19 患者的临床病程:韩国大邱的一项多中心研究。
Heart Lung. 2021 Jan-Feb;50(1):21-27. doi: 10.1016/j.hrtlng.2020.10.010. Epub 2020 Oct 19.
2
Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.中国上海 2019 年冠状病毒病的体外膜肺氧合治疗。
ASAIO J. 2020 May;66(5):475-481. doi: 10.1097/MAT.0000000000001172.
3
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study.体外膜肺氧合治疗 COVID-19 相关严重急性呼吸窘迫综合征的回顾性队列研究。
Lancet Respir Med. 2020 Nov;8(11):1121-1131. doi: 10.1016/S2213-2600(20)30328-3. Epub 2020 Aug 13.
4
Implementation of new ECMO centers during the COVID-19 pandemic: experience and results from the Middle East and India.COVID-19 大流行期间新的体外膜肺氧合(ECMO)中心的实施:来自中东和印度的经验和结果。
Intensive Care Med. 2021 Aug;47(8):887-895. doi: 10.1007/s00134-021-06451-w. Epub 2021 Jun 22.
5
First successful treatment of a COVID-19 pregnant woman with severe ARDS by combining early mechanical ventilation and ECMO.首例 COVID-19 重症 ARDS 孕妇成功采用早期机械通气联合 ECMO 治疗。
Heart Lung. 2021 Jan-Feb;50(1):33-36. doi: 10.1016/j.hrtlng.2020.08.015. Epub 2020 Aug 21.
6
[Study on the extracorporeal membrane oxygenation inter-hospital transport during coronavirus disease 2019 epidemic: based on the transport experience of 6 cases of severe H1N1 influenza virus pneumonia on extracorporeal membrane oxygenation].新型冠状病毒肺炎疫情期间体外膜肺氧合院际转运的研究:基于6例体外膜肺氧合治疗的重症甲型H1N1流感病毒肺炎患者的转运经验
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Apr;32(4):430-434. doi: 10.3760/cma.j.cn121430-20200309-00413.
7
Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome.体外膜肺氧合治疗2009年甲型H1N1流感所致急性呼吸窘迫综合征
JAMA. 2009 Nov 4;302(17):1888-95. doi: 10.1001/jama.2009.1535. Epub 2009 Oct 12.
8
Thromboembolic and Bleeding Events in COVID-19 Patients receiving Extracorporeal Membrane Oxygenation.COVID-19 患者接受体外膜肺氧合治疗后的血栓栓塞和出血事件。
Thorac Cardiovasc Surg. 2021 Sep;69(6):526-536. doi: 10.1055/s-0041-1725180. Epub 2021 Apr 16.
9
Extracorporeal Membrane Oxygenation for Severe Respiratory Failure During Respiratory Epidemics and Pandemics: A Narrative Review.体外膜肺氧合在呼吸道传染病和大流行期间治疗严重呼吸衰竭:一项叙述性综述。
Ann Acad Med Singap. 2020 Apr;49(4):199-214.
10
Evolving outcomes of extracorporeal membrane oxygenation support for severe COVID-19 ARDS in Sorbonne hospitals, Paris.巴黎索邦大学医院严重 COVID-19 急性呼吸窘迫综合征体外膜肺氧合支持的治疗结果演变。
Crit Care. 2021 Oct 9;25(1):355. doi: 10.1186/s13054-021-03780-6.

引用本文的文献

1
Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis.需要体外膜肺氧合的新型冠状病毒肺炎患者的血栓形成与出血:一项系统评价和荟萃分析
Res Pract Thromb Haemost. 2023 Feb;7(2):100103. doi: 10.1016/j.rpth.2023.100103. Epub 2023 Mar 8.
2
Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis.COVID-19 大流行的头 2 年中体外膜肺氧合的治疗结局变化:系统回顾和荟萃分析。
Crit Care. 2022 May 23;26(1):147. doi: 10.1186/s13054-022-04011-2.
3
Mortality in patients with COVID-19 requiring extracorporeal membrane oxygenation: A meta-analysis.

本文引用的文献

1
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study.体外膜肺氧合治疗 COVID-19 相关严重急性呼吸窘迫综合征的回顾性队列研究。
Lancet Respir Med. 2020 Nov;8(11):1121-1131. doi: 10.1016/S2213-2600(20)30328-3. Epub 2020 Aug 13.
2
Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America.COVID-19 患者呼吸衰竭的静脉-静脉体外膜肺氧合:来自北美的一家主要学术医疗中心的早期经验。
Ann Surg. 2020 Aug;272(2):e75-e78. doi: 10.1097/SLA.0000000000004084.
3
需要体外膜肺氧合的新型冠状病毒肺炎患者的死亡率:一项荟萃分析。
World J Clin Cases. 2022 Mar 16;10(8):2457-2467. doi: 10.12998/wjcc.v10.i8.2457. Epub 2022 Jan 16.
4
The role of vitamin B12 in viral infections: a comprehensive review of its relationship with the muscle-gut-brain axis and implications for SARS-CoV-2 infection.维生素 B12 在病毒感染中的作用:对其与肌肉-肠道-大脑轴关系的综合回顾及其对 SARS-CoV-2 感染的影响。
Nutr Rev. 2022 Feb 10;80(3):561-578. doi: 10.1093/nutrit/nuab092.
5
Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.体外膜肺氧合治疗 COVID-19 的系统评价和荟萃分析。
Crit Care. 2021 Jun 14;25(1):211. doi: 10.1186/s13054-021-03634-1.
6
The incidence, clinical characteristics, and outcomes of pneumothorax in hospitalized COVID-19 patients: A systematic review.COVID-19 住院患者气胸的发病率、临床特征和结局:系统评价。
Heart Lung. 2021 Sep-Oct;50(5):599-608. doi: 10.1016/j.hrtlng.2021.04.005. Epub 2021 May 1.
Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients.
体外膜肺氧合治疗 2019 年冠状病毒病所致严重肺和心功能障碍:32 例患者的经验。
ASAIO J. 2020 Jul;66(7):722-730. doi: 10.1097/MAT.0000000000001185.
4
Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China.中国武汉 221 例 COVID-19 患者的临床特征和短期预后。
J Clin Virol. 2020 Jun;127:104364. doi: 10.1016/j.jcv.2020.104364. Epub 2020 Apr 9.
5
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
6
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局:一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
7
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病(COVID-19)疫情的特征及重要经验教训:来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
9
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征:描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
10
The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance.源自中国武汉的新型冠状病毒:全球卫生治理面临的挑战
JAMA. 2020 Feb 25;323(8):709-710. doi: 10.1001/jama.2020.1097.